SPDR S&P Pharmaceuticals ETF
XPH - ETF AI Analysis
Top Page
SPDR S&P Pharmaceuticals ETF (XPH)
XPH’s rating reflects a mix of solid, established pharma names and more financially challenged companies. Strong contributors like Eli Lilly and Zoetis, which show robust financial performance and strategic initiatives such as dividends and share repurchases, help support the fund’s quality. However, weaker holdings like Xeris Pharmaceuticals, with high leverage and negative equity, and others facing profitability or cash flow issues add risk, and the fund’s focus on the pharmaceutical sector means investors are exposed to sector-specific pressures.
XPH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 528.86M
- Region
- North America
- Expense Ratio
- 0.35%
- Beta
- 0.77
- Issuer
- SPDR
- Inception Date
- Jun 19, 2006
- Dividend Yield
- 0.41%
- Asset Class
- Equity
- Index Tracked
- S&P Pharmaceuticals Select Industry
XPH Summary
XPH is the SPDR S&P Pharmaceuticals ETF, which follows the S&P Pharmaceuticals Select Industry index. It focuses on U.S. drugmakers, from smaller innovators to big, well-known names like Eli Lilly and Pfizer. By investing in XPH, you get a basket of pharmaceutical companies in one trade, which can offer growth potential tied to new medicines and rising health care needs, along with diversification within the drug sector. However, because it is heavily focused on pharmaceuticals, its price can go up and down sharply with changes in drug approvals, regulation, and overall health care market sentiment.
How much will it cost me?
This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s higher than the cost of a typical broad, passively managed index ETF because this fund focuses on a specialized pharmaceuticals sector index, which usually comes with slightly higher fees.
What would affect this ETF?
XPH could benefit from growing health care demand, an aging population, and successful new drugs from its U.S. pharmaceutical holdings like Eli Lilly, Pfizer, and smaller specialty firms, especially if regulations remain supportive of innovation and insurance coverage. On the downside, tighter drug pricing rules, patent expirations, safety or approval setbacks, and broader market or economic stress in the U.S. could hurt profits and weigh on the ETF’s performance.
XPH Top 10 Holdings
XPH is a pure play on U.S. pharmaceuticals, and its story right now is driven more by nimble drug developers than by household names. Pacira and Amneal have been rising steadily, giving the fund a solid lift, while Ligand and Viatris add to the momentum with improving trends despite some valuation worries. On the flip side, Maze Therapeutics has been lagging, acting like a small anchor on an otherwise upbeat portfolio. With Eli Lilly as a steady blue-chip presence, the ETF is clearly concentrated in pharma innovators rather than broad health care giants.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Xeris Pharmaceuticals | 4.30% | $22.76M | $3.04B | 129.48% | 46Neutral | |
| Veradermics, Incorporated | 2.70% | $14.31M | $5.47B | 243.47% | ―― | |
| Maze Therapeutics, Inc. | 2.60% | $13.77M | $1.88B | 7.82% | 59Neutral | |
| Eli Lilly & Co | 2.53% | $13.38M | $1.36T | 41.12% | 72Outperform | |
| Viatris | 2.49% | $13.20M | $23.87B | 90.83% | 60Neutral | |
| Pacira Pharmaceuticals | 2.53% | $13.39M | $1.46B | 54.36% | 69Neutral | |
| Amneal Pharmaceuticals | 2.50% | $13.26M | $7.45B | 85.59% | 58Neutral | |
| Septerna, Inc. | 2.05% | $10.87M | $2.03B | 121.41% | 61Neutral | |
| Eton Pharmaceuticals | 2.08% | $11.01M | $1.84B | 278.73% | 56Neutral | |
| Royalty Pharma | 2.27% | $12.00M | $39.76B | 74.45% | 79Outperform |
XPH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XPH, the sentiment is Positive. The current price of 66.83 is above the 20-day moving average (MA) of 64.87, above the 50-day MA of 65.41, and above the 200-day MA of 62.15, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 55.28 is Neutral, neither overbought nor oversold. The STOCH value of 78.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XPH.
XPH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $66.83 | $67.00(0.25% Upside) | $528.86M | 0.35% | 58Neutral | |
| $131.04 | $161.99(23.62% Upside) | $609.17M | 0.58% | 70Neutral | |
| $97.88 | $127.65(30.41% Upside) | $436.74M | 0.59% | 71Outperform | |
| $39.98 | $52.19(30.54% Upside) | $344.66M | 0.51% | 67Neutral | |
| $57.32 | $78.31(36.62% Upside) | $284.20M | 0.60% | 60Neutral | |
| $145.43 | $171.17(17.70% Upside) | $244.82M | 0.35% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XPH | SPDR S&P Pharmaceuticals ETF | 66.83 | 15.68 | 30.67% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 131.04 | 29.07 | 28.51% | |
| PBE | Invesco Dynamic Biotechnology & Genome ETF | 97.88 | 21.54 | 28.21% | |
| PINK | Simplify Health Care ETF | 39.98 | 3.96 | 11.00% | |
| PTH | Invesco DWA Healthcare Momentum ETF | 57.31 | 8.61 | 17.68% | |
| XHS | SPDR S&P Health Care Services ETF | 145.43 | 44.02 | 43.41% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
